September 02, 2020
Dutch Medicines Evaluation Board announced the overview of undesirable switching of medicines
The report will be prepared by the Medicines Evaluation Board (College ter Beoordeling van Geneesmiddelen) at the request of the Ministry of Health, Welfare and Sport in the interest of patient safety.

Generic medicines are just as effective and safe as the original medicines with the same active ingredient. The CBG assesses applications for the registration of new generic drugs based on this. Medicines with the same active ingredient, dosage, and method of administration are usually interchangeable as they have been shown to have a similar effect. Nevertheless, switching sometimes may lead to unrest, dissatisfaction, or even health problems.

The CBG has compiled an overview of medicines where changes are undesirable because the change can lead to serious health complaints. The CBG first draw up scientific conditions for this and discussed these conditions with patient organizations and umbrella organizations of doctors, pharmacists, and health insurers. On this basis, the CBG makes the selection for the overview of medicines that are preferably not switched because of a health risk.

The overview is expected to be completed by the end of 2020 and will then be evaluated annually.

The full details can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)